Recombinant Human PSMA / FOLH1 Protein, Fc Tag, premium grade, 100 µg

Background
Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily. FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.

Source
Recombinant Human PSMA, Fc Tag (PSA-H5264) is expressed from human 293 cells (HEK293). It contains AA Lys 44 - Ala 750 (Accession # Q04609-1).
Predicted N-terminus: Pro
It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Molecular Characterization
This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 106.0 kDa. The protein migrates as 110-140 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.01 EU per μg by the LAL method.

Sterility
The sterility testing was performed by membrane filtration method.

Mycoplasma
Negative.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer"
Enke, Groß, Grosser et al
BMC Cancer (2024) 24 (1), 65
(2) "Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: clinical and PET/CT features to predict outcomes and prognosis"
Luo, Wang, Wang et al
Clin Radiol (2024)
(3) "Diagnostic accuracy of bone scan at different PSA levels in biochemical recurrence of prostate cancer"
Singh, London, Wong et al
J Med Imaging Radiat Sci (2024)
Showing 1-3 of 6174 papers.